Biotech · Private company · Portland, OR, US
Torralva Medical Therapeutics, LLC
Track this companyFree. Adds Torralva Medical Therapeutics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.Fiscal year 2025 · $100KNIH RePORTER 3R44DA056267-02S1 · fetched Nov 12, 2026
- Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.Fiscal year 2025 · $446.8KNIH RePORTER 5R44DA056267-03 · fetched Nov 12, 2026
- Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.Fiscal year 2024 · $522.9KNIH RePORTER 4R44DA056267-02 · fetched Nov 12, 2026